A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2).

CONCLUSIONS: We propose that increased expression of RRM2 is a mechanism driving poor patient outcomes in PC and that its inhibition may be of significant therapeutic value.
PMID: 30996073 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 16, 2019 Category: Cancer & Oncology Authors: Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins S, Nandakumar S, Gerke T, Pomerantz M, Qiu X, Zhao H, Atiq MO, Khan NA, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long H, Freedman M, Kim B, Kantoff PW Tags: Clin Cancer Res Source Type: research